Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Sangamo Therapeutics

Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.

Sangamo Therapeutics SGMO NASDAQ

Biotechnology company developing gene therapies and genome editing.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 2 Completed 3 Terminated 1

Gene Editing's lasting impact: a 10-Year safety watch

Knowledge-focused Terminated

This study checks on people who previously received gene editing for hemophilia B or mucopolysaccharidosis (MPS) I or II. No new treatment is given; instead, participants are monitored for up to 10 years to see if any new health problems or worsening of existing conditions appear…

Sponsor: Sangamo Therapeutics • Aim: Knowledge-focused

Last updated Aug 15, 2026 00:00 UTC